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E-mail: allison.ashleykoch@duke.edu Low birth weight is associated with increased risk for Attention­
Deﬁcit/Hyperactivity Disorder (ADHD); however, the etiologi­
cal underpinnings of this relationship remain unclear. This study 
investigated if genetic variants in angiogenic, dopaminergic, 
neurotrophic, kynurenine, and cytokine-related biological path­
ways moderate the relationship between birth weight and ADHD 
symptom severity. A total of 398 youth from two multi-site, 
family-based studies of ADHD were included in the analysis. The 
sample consisted of 360 ADHD probands, 21 affected siblings, 
and 17 unaffected siblings. A set of 164 SNPs from 31 candidate 
genes, representing ﬁve biological pathways, were included in 
our analyses. Birth weight and gestational age data were collected 
from a state birth registry, medical records, and parent report. Generalized Estimating Equations tested for main effects and 
interactions between individual SNPs and birth weight centile in 
predicting ADHD symptom severity. SNPs within neurotrophic 
(NTRK3) and cytokine genes (CNTFR) were associated with 
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Am J Med Genet Part B 165B:691–704. ADHD inattentive symptom severity. There was no main effect of 
birth weight centile on ADHD symptom severity. SNPs within 
angiogenic (NRP1 & NRP2), neurotrophic (NTRK1 & NTRK3), 
cytokine (IL16 & S100B), and kynurenine (CCBL1 & CCBL2) 
genes moderate the association between birth weight centile and 
ADHD symptom severity. The SNP main effects and SNP x birth 
weight centile interactions remained signiﬁcant after adjusting 
for multiple testing. Genetic variability in angiogenic, neuro­
trophic, and inﬂammatory systems may moderate the associa­
tion between restricted prenatal growth, a proxy for an adverse 
prenatal environment, and risk to develop ADHD. 
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Attention-Deﬁcit/Hyperactivity Disorder (ADHD) is character­
ized by persistent, pervasive, and developmentally inappropriate 
levels of inattention, hyperactivity-impulsivity, or both. ADHD 
arises from the complex interplay between genetic and environ­
mental factors [Thapar et al., 2013]. Consequently, there are likely 
to be multiple etiological pathways leading from early risk to the 
development of the disorder [Sonuga-Barke and Halperin, 2010; 
Thapar et al., 2013]. In particular, environmental insults during 
prenatal development have the potential to have lasting effects on 
neurodevelopmental risk for ADHD [Lou, 1996; Toft, 1999; Lou 
et al., 2004; Mill and Petronis, 2008]. Although multiple prenatal 
environmental risk factors for ADHD have been identiﬁed [Bane­
rjee et al., 2007; Nigg et al., 2010; Froehlich et al., 2011], speciﬁc 
developmental mechanisms that contribute to the emergence of 
ADHD are poorly understood. 
Restricted fetal growth phenotypes, like low birth weight 
(<2,500 g) and small for gestational age, are among the strongest 
risk factors for ADHD and lead to 1.5 to 3-fold increase in ADHD 
risk [Breslau et al., 1996; Mick et al., 2002; Indredavik et al., 2004; 
Linnet et al., 2006; Boulet et al., 2009]. The strength of this 
association, however, varies across studies [Nigg, 2006] and is not 
always replicated [Cornforth et al., 2012]. Consistent with the 
dimensional nature of ADHD [Levy et al., 1997; Coghill and 
Sonuga-Barke, 2012], the association between lower birth weight 
and ADHD-related phenotypes is continuous and extends into 
the normal birth weight range [Boulet et al., 2009; Phua 
et al., 2012; Qiu et al., 2012; Walhovd et al., 2012]. Lower birth 
weight is also associated with reduced anterior cingulate cortex, 
caudate nucleus, and total brain volumes [Peterson et al., 2003; 
Tolsa et al., 2004; de Kieviet et al., 2012; Walhovd et al., 2012], 
which are linked with ADHD behavioral symptomatology [Frodl 
and Skokauskas, 2012; Hart et al., 2013]. Identifying biological 
mechanisms that contribute to the association between lower 
birth weight and ADHD may further elucidate early develop­
mental pathways to ADHD. Similar to ADHD [Thapar et al., 2013], birth weight has multi-
factorial origins and a substantial heritability estimate [Mook-
Kanamori et al., 2012]. This allows for the possibility that birth 
weight and ADHD share a common genetic liability. Twin studies, 
however, demonstrate that prenatal environmental factors, rather 
than shared genetic factors, largely account for the relationship 
between birth weight and ADHD symptoms [Lehn et al., 2007; 
Groen-Blokhuis et al., 2011; Ficks et al., 2013; Sharp et al., 2003] or 
externalizing behavior [van Os et al., 2001; Wichers et al., 2002]. 
This suggests that environmental determinants of lower birth 
weight contribute to the development of ADHD. 
Suboptimal maternal-placental-fetal nutrient and oxygen trans­
port (e.g., placental insufﬁciency) is associated with restricted fetal 
growth in most cases [Ghidini, 1996; Hendrix et al., 2008]. Prenatal 
ischemia-hypoxia is considered the primary pathway to lower birth 
weight, especially in well-nourished populations [Henriksen et al., 
2002]. Placental insufﬁciency and fetal growth restriction are 
associated with altered angiogenic [Conde-Agudelo et al., 2013], 
dopaminergic [Vucetic et al., 2010], neurotrophic [Malamitsi-
Puchner et al., 2007], and inﬂammatory responses [Amarilyo 
et al., 2011], and numerous poor neurodevelopmental outcomes 
[Baschat, 2011]. Prenatal ischemia-hypoxia is a common element 
to multiple early risk factors for ADHD including maternal smok­
ing [Bush et al., 2000] and maternal alcohol use during pregnancy 
[Bosco and Diaz, 2012] as well as ischemia-hypoxia related obstetric 
complications [Pineda et al., 2007; Rennie et al., 2007; Getahun 
et al., 2013]. Consistent with the Developmental Origins of Health 
and Disease (DOHaD) framework [Gluckman et al., 2004; Mill 
et al., 2008; Swanson and Wadhwa, 2008; Swanson et al., 2009; 
Wadhwa et al., 2009], the association between lower birth weight 
and ADHD may arise from prenatal ischemia-hypoxia. Prenatal 
ischemia-hypoxia may directly disrupt or delay development or 
lead to structural or functional adaptations to the adverse intra­
uterine environment. Such adaptations, however, may leave the 
individual ill-equipped to function in a nutrient and oxygen rich 
postnatal environment. For example, in response to prenatal 
ischemia-hypoxia some fetuses preferentially redistribute blood 
ﬂow to the brain, known as the “brain-sparing effect” [Roza 
et al., 2008]. Fetuses that demonstrate “brain-sparing” circulation 
may be better protected from the immediate adverse effects of 
ischemia-hypoxia, however, these fetuses may exhibit decreased 
TABLE I. Sample Size by Site 
Site n % of total sample 
Ireland 33 8.3 
Netherlands - Amsterdam 101 25.4 
Netherlands - Nijmegen 73 18.3 
United Kingdom 84 21.1 
IMAGE Subtotal 291 73.1 
Duke 65 16.3 
UNCG 42 10.6 
NCGAP Subtotal 107 26.9 
Total Sample 398 100 cerebral vascular plasticity [Fu et al., 2006] and increased behavioral 
problems [Roza et al., 2008; Figueras et al., 2011]. Genetic variabil­
ity in key ischemia-hypoxia related developmental systems may 
further alter susceptibility to ADHD, following an adverse intra­
uterine environment. 
Few studies have investigated how the interplay between 
fetal growth and genetic variability contributes to ADHD’s complex 
pathophysiology. Langley et al. (2008) found that “classic” candi­
date neurotransmitter gene (DAT1, DRD4, DRD5, and SLC6A4) 
variants did not moderate the association between birth weight and 
ADHD. Another study reported that ADHD youth who also had 
low birth weight were at increased risk for early-onset antisocial 
behavior if they possessed the COMT Val/Val genotype [Thapar 
et al., 2005]. This ﬁnding, however, was not replicated in a separate 
ADHD clinical sample [Sengupta et al., 2006]. To examine mech­
anisms linking fetal growth with ADHD, it may be important to 
broaden the search to genes implicated in the response to prenatal 
ischemia-hypoxia, a main determinant of restricted fetal growth. 
Prenatal ischemia-hypoxia impacts multiple neurodevelopmen­
tal systems [Schmidt-Kastner et al., 2012; Zhang et al., 2012; Wang 
et al., 2013]. Of the many systems implicated in the ischemia­
hypoxia response, dopaminergic [Levy, 1991; Swanson et al., 2007], 
neurotrophic [Ribases et al., 2008; Sanchez-Mora et al., 2009], 
angiogenic [Kim et al., 2002; Jesmin et al., 2004], kynurenine 
[Oades, 2011] and cytokine systems [Oades, 2011] are also impli­
cated in the development of ADHD and related conditions. There­
fore, genetic variants within these ﬁve systems were the focus of this 
study. Variability in genes regulating these systems may alter 
vulnerability to the effects of prenatal ischemia-hypoxia leading 
to the neurodevelopmental deﬁcits that mediate the ADHD behav­
ioral phenotype [Toft, 1999; Shaw et al., 2006; Rapoport and 
Gogtay, 2008]. To address this hypothesis, we examined interac­
tions between genetic variants within ischemia-hypoxia response 
systems and birth weight centile, adjusted for gestational age, to 
predict ADHD symptom severity. We predicted that: (i) lower birth 
weight centile would be associated with increased ADHD symp­
tomatology; and (ii) SNPs within dopaminergic, neurotrophic, 
angiogenic, kynurenine and cytokine system genes would moderate 
the association between birth weight centile and ADHD symptom 
severity. 
MATERIALS AND METHODS 
Subjects 
Participants were drawn from two larger studies - the North 
Carolina Genetics of ADHD Project [NCGAP; Kollins 
et al., 2008; Anastopoulos et al., 2011] and the International 
Multisite ADHD Genetics Project [IMAGE; Brookes et al., 2006; 
Kuntsi et al., 2006; Neale et al., 2008b], the latter including 12 
enrollment sites within Europe and Israel. The current analysis was 
conducted on a subset of the NCGAP and IMAGE samples who 
were singleton births and had birth weight, gestational age, and 
genome-wide single nucleotide polymorphism (SNP) data. Birth 
weight and gestational age data were only available for IMAGE 
study sites in the United Kingdom, Ireland and the Netherlands. 
Furthermore, we only included Caucasian participants due to 
genotype imputation procedures (described below). Of the 398 youth in the ﬁnal sample (Table I), 86% met criteria for DSM-IV 
ADHD Combined Type (n ¼ 327), 11% met for ADHD Inattentive 
Type (n ¼ 42), 3% met for ADHD Hyperactive-Impulsive Type 
(n ¼ 12), and 4% were unaffected (n ¼ 17). For NCGAP [Anasto­
poulos et al., 2011] and IMAGE [Neale et al., 2008a], DSM-IV 
ADHD diagnoses were based on parental responses to a clinical 
interview as well as teacher and/or parent responses to behavior 
rating scales. This study was approved by the afﬁliated institutional 
review boards and conducted in accordance with human subjects 
guidelines. Measures 
Conners’ parent rating scale (CPRS; Conners, 1997). Parent 
responses to the CPRS 18-item DSM-IV ADHD total subscale, as 
well as 9-item Inattentive and Hyperactive–Impulsive subscales 
were summed and converted to t-scores adjusting for age and 
gender of each participant [Conners et al., 1998]. Parents were 
instructed to rate their child’s ADHD symptoms when not taking 
medication prescribed for ADHD. The resulting scores were con­
tinuous measures of ADHD symptom severity and served as out­
comes in this study. The CPRS ADHD Total (skewness ¼ -0.81; 
SE ¼ 0.12), Inattentive (skewness ¼-0.50; SE ¼ 0.12), and Hyper­
active–Impulsive (skewness ¼-0.85; SE ¼ 0.12) scores were non-
normally distributed. Therefore, transformed CPRS ADHD Total 
(square root of reﬂected score transformation; skewness ¼-0.03; 
SE ¼ 0.12), Inattentive (squared transformation; skewness ¼ 
<0.01; SE ¼ 0.12), and Hyperactive–Impulsive scores (square 
root transformation; skewness ¼-0.07; SE ¼ 0.12) were selected 
for analysis based on normality. 
Birth weight centile range. Birth weight centiles were calculat­
ed for each participant adjusting for gestational age and sex, based 
on separate normative samples for the Netherlands, United King-
dom/Ireland, and United States participants. 
NCGAP. Birth weight and gestational age for the NCGAP 
sample was retrieved through medical records, parental report, 
and state birth registry. Birth weight centiles for NCGAP were 
created using all singleton births from 2000xps12004 from the 
CDC National Vital Statistics natality ﬁles. For consistency, indi­
vidual centiles were then converted to the centile ranges described 
below. 
IMAGE. For the Dutch sample, birth weight and gestational age 
were obtained through retrospective parent report. The 
Netherlands Perinatal Registry reference curves were used to cal­
culate birth weight centiles for the Dutch sample [Visser 
et al., 2009]. The Netherlands Perinatal Registry reference curves 
provide 11 normative references at 2.3, 5, 10, 16, 20, 50, 80, 84, 90, 
95, and 97.7 centiles [Visser et al., 2009]. Therefore, 12 birth weight 
centile ranges were created (0–2.29, 2.3–4.9, 5–9.9, 10–15.9, 16– 
19.9, 20–49.9, 50–79.9, 80–83.9, 84–89.9, 90–94.9, 95–97.6, 97.7– 
100). Lower scores on the resulting ordinal severity scale of birth 
weight centile ranges represented higher levels of fetal growth 
restriction. 
Birth weight and gestational age for samples from Ireland and the 
UK were obtained from retrospective parent report. The UK 
reference curves [Pan et al., 2010; Cole et al., 2011] were used to 
calculate birth weight centiles for the UK and Ireland samples, based 
on birth weight, gestational age, and sex. For consistency, individual 
birth weight centiles were converted to birth weight centile ranges 
identical to those created in the Dutch sample. 
Genotyping. SNP genotyping for the NCGAP subsample 
was performed using the Illumina Inﬁnium HumanHap300 duo 
(Illumina, Inc., San Diego, CA) at the Center for Human Genetics 
at Duke University Medical School. Two Centre d’Etude du 
Polymorphism Humain (CEPH) controls and blinded duplicates 
were used for every 94 samples and required to match 100%. 
Additional quality checks of the genotyping data were examined 
using PLINK [Purcell et al., 2007]. Call rates exceeded 98% for all 
individuals. Individuals were excluded due to gender discrepancy 
and if per-family Mendelian errors were in excess of 1%. SNPs 
were excluded from analysis if they had Mendelian errors in >4 
families or deviated from Hardy-Weinberg Equilibrium (HWE; 
P < 0.000001). 
SNP genotyping for the IMAGE subsample was performed at 
Perlegen Sciences (Mountain View, CA) on a microarray designed 
for the Genetic Association Information Network (GAIN). Quality 
checks were completed by the National Center for Biotechnology 
Information (NCBI) using GAIN QA/QC, version 0.7.4 [Abecasis 
Gopalakirshnana]. Individuals were excluded due to gender dis­
crepancy and if per-family Mendelian errors were in excess of 2%. 
SNPs were excluded if the: (i) call rate was <95%; (ii) heterozygosity 
was >32%; (iii) discrepancy in SNP call was <10% in whole sample; 
or (iv) HWE P < 0.000001. 
Candidate genes were selected based of literature review of 
candidate signaling pathways [Reichardt, 2006; Shibuya, 2008], 
ischemia–hypoxia response genes [Schmidt-Kastner et al., 2006], 
ADHD etiological studies [Gizer et al., 2009; Oades et al., 2010; 
Oades, 2011] and genotyping platform coverage. SNPs within 
dopaminergic (COMT, DAT1, DRD2, DRD3, and DRD5), neuro­
trophic (BDNF, NGF, NT3, NGFR, NTRK1, NTRK2, and NTRK3), 
angiogenic (VEGFA, VEGFR1, VEGFR2, NRP1, NRP2, HIF1A, 
and HIF1AN), kynurenine (CCBL1, CCBL2, and KYNU) and 
cytokine related genes (CNTF, CNTFR, CRLF1, IL6, IL13, IL16, 
LIF, LIFR, and S100B) that passed quality control measures were 
considered for inclusion in the analysis. To increase genetic overlap 
across NCGAP and IMAGE, genotype data were imputed with 
the use of the phased data from the HapMap samples (CEU; 
build 36, release 22) and MACH [http://www.sph.umich.edu/ csg/abecasis/MaCH/download; Li et al., 2009, 2010]. Imputed 
SNPs with an R2 value <0.3, indicating poor imputation quality, 
were excluded from analysis (see Supplementary Table SI for 
SNP imputation quality). Note that not all SNPs attributed to 
candidate genes in this build are attributed to the same genes in 
NCBI build 37. 
A total of 2,014 dopaminergic, neurotrophic, angiogenic, 
kynurenine and cytokine SNPs were available for this study and 
submitted for quality checks. The majority of these SNPs were not 
functional. To reduce the number of statistical tests conducted, 
remaining SNPs with a: (i) minor allele frequency (MAF) <0.1; (ii) 
genotype frequency below seven; or (iii) in linkage disequilibrium 
(LD; R2 ; 0.64) were eliminated. A total of 164 SNPs in dopami­
nergic, neurotrophic, angiogenic, kynurenine, and cytokine sys­
tems remained. Data Analysis 
Bivariate correlations and Pearson product-moment correlation 
coefﬁcients examined the associations among demographic, peri­
natal risk, and ADHD variables. In addition, t-tests and ANOVAs 
were used to test for differences between demographic groups on 
perinatal and ADHD variables. Alpha was set at 0.01 for these 
analyses. 
Generalized Estimating Equations (GEEs) tested for main effects 
of SNP genotype and birth weight centile range, and the interaction 
between SNP and birth weight centile range in predicting ADHD 
symptom severity. Given that within family data are more corre­
lated than between family data, GEEs account for the family 
correlation among siblings within the sample. An independent 
working correlation matrix and the model-based robust estimator 
covariance matrix were selected, which provides a reliable covari­
ance estimate even when the correlation matrix is not correctly 
speciﬁed. 
Linear GEEs were employed to test the SNP and birth weight 
centile range main effects on ADHD symptom severity after adjust­
ing for research site, age, and sex as covariates. Next, to test the 
hypothesis that SNP genotype moderates the association between 
birth weight centile and ADHD symptom severity, the covariates of 
site, age, and sex and main effects of SNP genotype and birth weight 
centile range were entered into the model, followed by the SNP x 
birth weight centile range interaction. Wald chi-square tests calcu­
lated with Type III sums of squares tested the signiﬁcance of main 
and interactive effects. In addition, continuous variables were 
centered to ease the interpretation of model effects. No speciﬁc 
genetic model was assumed in the primary analysis, as the genetic 
model could differ depending on the genetic variant. Additive, 
dominant, and recessive genetic models were tested on a secondary 
basis. 
In the GEEs, alpha was set at .01 for nominally signiﬁcant 
ﬁndings. A total of 164 independent GEEs were calculated. The 
Benjamini–Hochberg False Discovery Rate (FDR) test [Benjamini 
and Hochberg, 1995] was used to adjust for multiple comparisons. 
The FDR q-value threshold was set at 0.05 to determine statistical 
signiﬁcance. This study is adequately powered to detect reasonably 
sized SNP x birth weight centile interactions on ADHD without 
accounting for multiple testing and is underpowered to detect 
interactions after FDR correction (Supplementary Table SII). 
Exploratory Sobel tests were conducted to examine if birth weight 
centile mediated the effect of SNPs on ADHD symptom severity. All 
analyses were completed using SAS. 
RESULTS 
Demographic, Perinatal, and ADHD Variables 
A total of 398 youth participated in the current study (see Table I for 
sample size by site), including 360 ADHD probands, 21 affected 
siblings, and 17 unaffected siblings. The sample had a mean age of 
10.7 years (SD ¼ 3.02 years; range 5–17 years) and was 83% male. In 
terms of birth characteristics, the samples’ mean birth weight 
(M ¼ 3,389.25 g; SD ¼ 565 g) and gestational age (M ¼ 39.56 
weeks; SD ¼ 1.94 weeks) were in the normal range. 
Table II gives a summary of the relationships between continu­
ous demographic, perinatal, and ADHD variables. Older youth had 
lower birth weight centile range scores and higher CPRS ADHD 
Total scores. There were no differences between females and males 
in birth weight centile range (t(396) ¼ 0.67, p ¼ 0.50), birth weight 
(t(396) ¼N-0.707, p ¼ 0.48), or gestational age (t(396) ¼ 0.72, 
p ¼ .47). 
Birth weight centile range scores, varied across data collection 
sites, F(5, 397) ¼ 8.34, P < 0.01 (Duke, M ¼ 6.92, SD ¼ 0.28; 
UNCG, M ¼ 7.98, SD ¼ 0.34; Ireland, M ¼ 6.26, SD ¼ 0.24; 
Netherlands–Amsterdam, M ¼ 5.77, SD ¼ 0.22; Netherlands–Nij­
megen, M ¼ 5.88, SD ¼ 0.26; UK, M ¼ 7.24, SD ¼ 0.39). In addi­
tion, CPRS ADHD Total scores varied across data collection sites, 
F(5, 397) ¼ 4.09, P < 0.01. In general, IMAGE samples had higher 
CPRS ADHD Total scores compared to the NCGAP samples (Duke, 
M ¼ 74.24, SD ¼ 13.96; UNCG, M ¼ 75.19, SD ¼ 14.49; Ireland, 
M ¼ 79.27, SD ¼ 9.26; Netherlands–Amsterdam, M ¼ 76.35, SD 
¼ 8.22; Netherlands–Nijmegen, M ¼ 78.32, SD ¼ 7.82; UK, 
M ¼ 81.58; SD ¼ 8.33). 
Analysis of SNP main effects on ADHD symptom severity. 
After controlling for site, age, sex, and multiple testing, three out 
of 164 SNPs had a signiﬁcant main effect on the CPRS Inatten­
tive score (see Table III and Supplementary Tables SVII and 
SVIII for SNP main effects from each statistical model). In the 
cytokine system, rs10758268 (CNTFR; q ¼ 0.005) and rs7044318 
(CNTFR; q ¼ 0.021) genotypes were associated with the CPRS 
Inattentive score. In the neurotrophic system, rs3825885 TABLE II. Correlations Between Selected De
Age CPRS A
Age — 
CPRS ADHD Total 0.21a 
Birth Weight Centile Range -0.14a 0
Birth Weight (g) -0.08 0
Gestational Age 0.08 0
Note: N  ¼ 398. CPRS, Conners’ Parent Rating Scale. 
aCorrelation is signiﬁcant at the 0.01 level (2-tailed). (NTRK3; q ¼ 0.021) genotype predicted the CPRS Inattentive 
score. SNP main effects on ADHD Total Score and Hyperactivi­
ty–Impulsivity were not signiﬁcant after adjusting for multiple 
testing (Table III). 
Main effect of birth weight centile range on ADHD symptom 
severity. Contrary to the ﬁrst hypothesis, birth weight centile 
range was not associated with ADHD Total (b ¼ 0.26; SE ¼ 0.21; 
95% CI ¼ -0.15–0.68; P ¼ 0.21), Inattentive (b ¼ 0.28; SE ¼ 0.20; 
95% CI ¼-0.11–0.67; P ¼ 0.16) or Hyperactive–Impulsive 
(b ¼ 0.14; SE ¼ 0.23; 95% CI ¼-0.30–0.59; P ¼ 0.53) scores. 
Note for interpretative purposes the above statistics are from 
non-transformed ADHD subscale models (P-values are consistent 
with transformed ADHD subscale models) 
Interactions between SNPs and birth weight centile on ADHD 
symptom severity. Out of the 164 interaction effects tested 
below without assuming a speciﬁc genetic model (Supplementary 
Table SIII), multiple SNP x birth weight centile interactions 
predicted ADHD symptom severity after multiple testing correc­
tion (Table IV). Signiﬁcant interactions included SNPs within 
angiogenic, neurotrophic, kynurenine, and cytokine systems. 
Speciﬁcally, for ADHD Total symptom severity, interactions 
between SNPs within the CCBL1, NTRK1, and NTRK3 
genes and birth weight centile range were signiﬁcant (Fig. 1). 
The interaction between a CCBL2 SNP and birth weight 
centile range predicted Inattentive symptom severity (Fig. 2). 
Finally, eleven SNPs in the CCBL1, CCBL2, IL16, NRP1, NRP2, 
NTRK1, NTRK3, and S100B genes moderated the association 
between birth weight centile range and Hyperactive-Impulsive 
symptom severity (Fig. 2). Interactions involving dopaminergic 
SNPs were no longer signiﬁcant after the multiple testing 
correction. 
Exploratory analyses were conducted assuming additive, domi­
nant, and recessive genetic models. Dominant genetic models 
produced ﬁve interactions predicting ADHD total score, two 
interactions predicting Inattentive symptom severity, and eleven 
interactions predicting Hyperactive-Impulsive score after multiple 
testing correction (Supplementary Table SIV). Fewer interactions 
were observed for additive and recessive genetic models (Supple­
mentary Tables SV and SVI, respectively). Finally, sobel tests did not 
provide evidence that the relationship between individual SNPs and 
ADHD symptom severity was mediated by birth weight centile for 
any of the models (results not shown). mographic, Perinatal, and ADHD Variables 
DHD total 
Birth weight 
centile range Birth weight (g) 
— 
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. DISCUSSION 
Examining biologically informed gene by environment interactions 
in ADHD may aid in the identiﬁcation of novel genes associated 
with ADHD and further the search for neurodevelopmental mech­
anisms underlying vulnerability for ADHD. Lower birth weight is 
commonly associated with ADHD [Nigg et al., 2010]; however, it is 
unclear what accounts for the phenotypic overlap between restrict­
ed fetal growth and ADHD. Therefore, this study examined whether 
SNPs within ischemia-hypoxia responsive systems interact with 
birth weight centile to predict ADHD symptom severity. 
Contrary to previous work, lower birth weight centile was not 
independently associated with increased ADHD symptom sever­
ity in our data set. In general, literature demonstrates there is an 
association between restricted fetal growth and ADHD symptom 
severity [Bhutta et al., 2002; Indredavik et al., 2004; Lahti 
et al., 2006], however, null ﬁndings have also been reported 
[Cornforth et al., 2012]. In this sample largely consisting of 
ADHD cases, levels of inattention and hyperactivity-impulsivity 
were elevated and represented the upper end of the ADHD risk 
spectrum. Thus, reduced variability in ADHD symptom severity 
in case-only [Langley et al., 2007] or family-based designs may 
have made the relationship between lower birth weight and 
ADHD more difﬁcult to detect. These results emphasize the 
heterogeneity in the relationship between lower birth weight 
and ADHD risk. 
Regarding genetic main effects, one SNP within NTRK3 (de­
scribed below) and two SNPs within CNTFR were associated with 
ADHD inattentive symptom severity, after adjusting for multiple 
testing. CNTFR encodes for ciliary neurotrophic factor receptor 
and is implicated in neurodevelopment and neuron survival 
[DeChiara et al., 1995]. In independent samples of children and 
adults, a three-marker CNTFR haplotype was associated with 
ADHD [Ribases et al., 2008]. Taken together, these ﬁndings suggest 
that CNTFR may be implicated in the development of ADHD. 
SNPs within angiogenic, neurotrophic, kynurenine, and cyto­
kine genes moderated the association between birth weight centile 
and ADHD symptom severity. In the neurotrophic pathway, 
NTRK1 and NTRK3 SNPs moderated the association between 
birth weight centile and ADHD total and hyperactive-impulsive 
symptom severity. NTRK1 and NTRK3 encode for tyrosine kinase 
receptors TrkA and TrkC, respectively. Nerve growth factor (NGF) 
preferentially binds to TrkA whereas neurotrophin-3 (NT3) binds 
at high afﬁnity to TrkC to promote neuron survival and synaptic 
plasticity [Lamballe et al., 1991; Reichardt, 2006], including in 
hypoxic conditions [Lee et al., 2003; Lin et al., 2006; Ishitsuka 
et al., 2012]. TrkA is expressed in various neuronal populations 
including cholinergic neurons in the basal forebrain and striatum 
[Holtzman et al., 1995]. TrkC is expressed throughout the brain and 
is most abundant in the hippocampus [Ernfors et al., 1992]. A 
previous molecular genetic study has implicated neurotrophic 
factors, especially, NT3, in ADHD risk, though not NTRK1 or 
NTRK3 [Ribases et al., 2008]. Additionally in the present study, one 
SNP within NTRK2 moderated the relationship between birth 
weight centile and ADHD hyperactive-impulsive symptoms at a 
trend level. Together these ﬁndings support the notion that neuro­
trophic receptor genotype is implicated in the development of 
TABLE IV. Summary of SNP and Birth Weight Centile Range Interactions (P < 0.01) Predicting the Transformed CPRS ADHD Total, 
Inattentive, and Hyperactive-Impulsive T-Scores 
SNP Main Effect Interaction 
p-value q-value p-value q-valuePhenotype System Gene SNP NCBI n MAF 
ADHD total NT NTRK1 rs962879 155113379 397 (C) 0.14 0.889 0.979 3E-06 4E-04* 
KYN CCBL1 rs10793967 130642111 397 (A) 0.15 0.805 0.949 1E-04 0.009* 
NT NTRK3 rs8037291 86308935 380 (G) 0.18 0.021 0.274 3E-04 0.016* 
NT NTRK3 rs17755717 86426100 377 (A) 0.18 0.454 0.852 0.003 0.088 
KYN CCBL2 rs4656076 89190875 389 (C) 0.23 0.261 0.697 0.003 0.088 
NT NTRK3 rs1017757 86355556 390 (G) 0.15 0.097 0.507 0.006 0.161 
ANG NRP2 rs17682318 206285589 391 (C) 0.3 0.998 0.998 0.008 0.188 
Inattentive KYN CCBL2 rs4656076 89190875 389 (C) 0.23 0.195 0.669 3E-04 0.049* 
CYTK IL16 rs11634770 79383455 397 (T) 0.13 0.785 0.953 6E-04 0.051 
NT NTRK3 rs8037291 86308935 380 (G) 0.18 0.048 0.426 0.003 0.159 
NT NTRK3 rs17755717 86426100 377 (A) 0.18 0.36 0.773 0.007 0.262 
ANG NRP1 rs2273466 33551053 397 (C) 0.19 0.269 0.689 0.008 0.262 
CYTK IL16 rs931963 79263756 393 (T) 0.15 0.706 0.926 0.01 0.264 
Hyperactive-impulsive NT NTRK3 rs8037291 86308935 380 (G) 0.18 0.153 0.719 4E-06 7E-04* 
NT NTRK1 rs962879 155113379 397 (C) 0.14 0.979 0.989 9E-06 7E-04* 
KYN CCBL2 rs10922552 89212813 387 (G) 0.11 0.422 0.793 8E-05 0.003* 
NT NTRK3 rs1017757 86355556 390 (G) 0.15 0.004 0.202 6E-05 0.003* 
KYN CCBL1 rs10793967 130642111 397 (A) 0.15 0.983 0.989 8E-05 0.003* 
ANG NRP1 rs2065364 33634008 395 (T) 0.29 0.809 0.982 2E-04 0.005* 
ANG NRP2 rs13419677 206266851 395 (C) 0.15 0.301 0.788 5E-04 0.013* 
ANG NRP1 rs2073320 33593263 396 (A) 0.4 0.883 0.988 0.001 0.021* 
NT NTRK3 rs2114251 86465797 384 (A) 0.15 0.868 0.988 0.001 0.023* 
CYTK IL16 rs8039027 79343327 393 (A) 0.24 0.628 0.917 0.002 0.026* 
CYTK S100B rs2839361 46848617 395 (C) 0.14 0.875 0.988 0.003 0.037* 
ANG NRP1 rs3780867 33587815 397 (A) 0.47 0.879 0.988 0.005 0.069 
NT NTRK2 rs11141486 86522947 396 (G) 0.31 0.862 0.988 0.008 0.099 
DA DRD3 rs963468 115345577 397 (A) 0.39 0.909 0.988 0.009 0.102 
Note. MAF, minor allele frequency; KYN, kynurenine; CYTK, cytokine; DA, dopaminergi c; NT, neurotrophic; ANG, angiogenic. ADHD and this relationship may depend on prenatal environmen­
tal inﬂuences, such as ischemia-hypoxia. 
The angiogenic system regulates the formation of new blood 
vessels. In the angiogenic system, NRP1 and NRP2 SNPs interacted 
with birth weight centile to predict hyperactive-impulsive symp­
tom severity. NRP1 and NRP2 encode for neuropilin-1 and neuro­
pilin-2, co-receptors for the vascular endothelial growth factor 
(VEGF) and semaphorin families [Pellet-Many et al., 2008]. 
NRP1 and NRP2 are expressed in the central nervous system 
and endothelial cells and play an essential role in vascular develop­
ment and axonal guidance [Polleux et al., 2000; Rossignol et al., 
2000; Gu et al., 2003; Pellet-Many et al., 2008]. Following cerebral 
ischemia, NRP1 disrupts axonal guidance near the ischemic area 
[Hou et al., 2008]. Further, NRP1 plays a central role coordinating 
neuronal migration and guidance of axons that project from the 
thalamus to the cortex [Lopez-Bendito et al., 2006], which has been 
implicated in the development of ADHD [Ivanov et al., 2010; 
Shaw, 2010] and externalizing behavior problems [Arcos-Burgos 
et al., 2012]. 
Cytokines are implicated in inﬂammatory, immune, and oxida­
tive stress responses [Capuron et al., 2011]. Genetic variation in IL16 and S100B interacted with birth weight centile to predict 
hyperactive-impulsive symptom severity. IL16 encodes for inter­
leukin-16 and regulates the inﬂammatory response [Cruikshank 
et al., 2008]. IL16 is expressed in T-cells, macrophages, and micro­
glia [Cruikshank et al., 2008; Jana et al., 2009]. S100B, a calcium 
binding protein, is a glial cytokine with neurotrophic properties 
[Steiner et al., 2007]. S100B is released in astrocytes following a 
restricted nutrient and oxygen supply [Gerlach et al., 2006]. Similar 
to the current ﬁndings, IL16 and S100B serum levels are associated 
with hyperactive-impulsive symptom severity within ADHD cases, 
and ADHD total symptom severity across cases and controls [Oades 
et al., 2010]. Within ADHD cases, S100B and IL16 serum levels have 
also been linked to pre- and perinatal risk factors including birth 
weight, gestational age, and maternal smoking during pregnancy 
[Oades, 2011], which makes them good candidates for a role in 
disease etiology. 
The kynurenine pathway metabolizes tryptophan and plays a 
role in glial and dopaminergic functioning, as well as inﬂammatory 
and immune responses [Steiner et al., 2012; Vecsei et al., 2013]. 
SNPs within CCBL1 and CCBL2 moderated the relationship be­
tween ADHD total, inattentive, and hyperactive-impulsive symp­
FIG. 1. Signiﬁcant SNP x birth weight centile interactions predicting ADHD total symptom severity. tom severity. CCBL1 and CCBL2 encode kynurenine aminotrans­
ferase I and II, respectively, which transaminate kynurenine into the 
neuroprotective kynurenic acid [Guillemin et al., 2007; Myint 
et al., 2007; Vecsei et al., 2013]. Kynurenic acid is an antagonist 
at the N-mehtyl D-aspartic acid (NMDA) and a7 nicotinic acety­
lochoine (a7nACH) receptors that are implicated in learning 
[Hilmas et al., 2001]. In rats, kynurenic acid in the prefrontal 
cortex is inversely related to glutamate, acetylcholine and dopamine 
levels, a relationship that has been detected even with minor 
changes in kynurenic acid [Wonodi et al., 2010]. In youth with 
ADHD, kynurenic acid in serum was positively associated with 
adverse events during the third trimester, at a trend level 
[Oades, 2011]. In light of these ﬁndings, prenatal ischemia-hypoxia 
may put individuals with susceptible CCBL1 and CCBL2 genotypes 
at risk for ADHD by leading to suboptimal expression of kynur­
enine aminotransferase I and II. Thus, variability in cytokine and 
kynurenine genes may alter risk for ADHD following exposure to 
pre- and perinatal risk, potentially by affecting glial functioning 
[Todd and Botteron, 2001; Russell et al., 2006; Oades et al., 2010]. 
We are encouraged by the promising ﬁndings of this study, but 
also recognize there are some study limitations. First, this study had 
a modest sample size and therefore, replication studies of these results are warranted. Second, youth in the study were either 
diagnosed with ADHD or at genetic risk for ADHD by nature of 
having a sibling with ADHD. This resulted in constrained variabil­
ity in ADHD symptom severity compared with the general popu­
lation which could have reduced statistical power and the likelihood 
of signiﬁcant ﬁndings. Third, birth weight centile range served as a 
proxy measure for an adverse intrauterine environment as no direct 
measure was available. Therefore, inferences about the underlying 
environmental pathogen were made in this study. Fourth, this 
design is unable to methodological control for genetic determinants 
of birth weight. This allows for the possibility that that genetic, 
rather than environmental determinants of birth weight are inter­
acting with SNPs to predict the ADHD phenotype. Fifth, we also 
acknowledge that we used an earlier NCBI build of the genome and 
as a result, some of the SNPs that we analyzed are now attributed to 
other genes. For example, SNPs identiﬁed in signiﬁcant interactions 
which are no longer attributed to the same gene include: rs962879 
(NTRK1 to CD1B), rs10793967 (CCBL1 to ABL1), rs4656076 
(CCBL2 to GBP3), rs10922552 (CCBL2 to intergenic region) 
and rs13419677 (NRP2 to PARD3B). Thus, it is possible that the 
association signals we detected are in LD with a genetic variant in a 
neighboring gene. Finally, the design of this study was unable to 
FIG. 2. Signiﬁcant SNP x birth weight centile interactions predicting inattentive and hyperactive-impulsive symptom dimensions. rule-out the effect of maternal genotype on the observed SNP x birth 
weight centile range interactions [Waldman, 2007]. Future research 
should include both maternal and child genotype when investigat­
ing the developmental origins of ADHD. 
Taken together, this study raises the possibility that angiogenic, 
neurotrophic, cytokine and kynurenine genetic variants moderate 
the association between birth weight and ADHD symptom severity. 
To our knowledge, this is the ﬁrst study to support the involvement 
of CCBL1, CCBL2, IL16, NRP1, NRP2, NTRK1, NTRK3, and S100B 
genes in the development of ADHD which highlights the impor­
tance of including measures of environmental risk when searching for novel genetic variants associated with ADHD. Although overall 
the pattern of results is consistent with expectations, we are 
pursuing replication datasets to further elucidate the relationships 
between these SNPs, birth weight centile, and ADHD risk. If 
replicated, these results provide a basis for future targeted gene 
methylation investigations. Findings also support the use of the 
DOHaD framework [Gluckman et al., 2004] in conceptualizing the 
etiological underpinnings of the association between lower birth 
weight and ADHD. Further application of this framework may aid 
in isolating speciﬁc prenatal environmental pathogens and genetic/ 
epigenetic pathways implicated in the development of ADHD. 
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